

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AdvanCell Pty Ltd.

Petitioner

v.

Sciencons AS

Patent Owner

Post Grant Review No.: PGR2025-00040

DECLARATION OF JENNIFER LIBRACH NALL, ESQ.

I, Jennifer Librach Nall, declare as follows:

1. My name is Jennifer Librach Nall, and I am an attorney duly admitted to practice before the Board. My USPTO Patent Bar Registration is 57,053, and I am in good standing. I am an attorney with DLA Piper LLP (US). I have personal knowledge of the facts set forth herein, except as to those stated on information and belief and, as to those, I am informed and believe them to be true. If called as a witness, I could and would competently testify to the matters stated herein.

2. I submitted Exhibit EX1024 in support of Petitioner's reply.

3. EX1024 is a true and correct copy of an excerpt from the homedepot.com front page as it existed on February 10, 2026, showing "National

Multi Purpose Seal(s)” in the “Inspired By Your Recent Views” section of the homedepot.com webpage.

4. I submitted Exhibit EX1025 in support of Petitioner’s reply.

5. EX1025 is a true and correct copy of an excerpt from vatgroup.com showing an 11.1 HV Gate Valve. PO’s expert, Charles Conroy, annotated a printed version of the webpage during his deposition. *See, e.g.*, EX1023 at 169:5–175:24. The webpage was accessed on March 5, 2026, and is accessible at <https://www.vatgroup.com/series/high-vacuum-gate-valve-standard/11136-PE01>. Although the webpage appears different from the exhibit, upon clicking “ctrl+p” (print), the webpage appears as it does in EX1025.

6. I submitted Exhibit EX1026 in support of Petitioner’s reply.

7. EX1026 is true and correct copy of a webpage article from Patent Owner ARTBIO’s website called, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials” that was published on May 7, 2024. The article was accessed on April 27, 2026 and is accessible at <https://artbio.com/artbio-nucleus-radiopharma-collaboration-manufacture-gmp-grade-therapeutic-products-radioisotope-pb-212-support-emerging-clinical-trials>.

8. I submitted Exhibit EX1027 in support of Petitioner’s reply.

9. EX1027 is true and correct copy of a webpage article by Fraiser Kansteiner called, “Nucleus RadioPharma Links Up With ARTBIO to Help Produce Prostate Cancer Candidate for Clinical Trials” that was published on the website FiercePharma.com on May 7, 2024. The article was accessed on March 26, 2026 and is accessible at <https://www.fiercepharma.com/pharma/nuclear-medicine-cdmo-nucleus-links-artbio-help-produce-prostate-cancer-radiotherapy>.

10. I submitted Exhibit EX1028 in support of Petitioner’s reply.

11. EX1028 is a true and correct copy of a webpage article from Patent Owner ARTBIO’s website called, “ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials” that was published on May 7, 2024. EX1022 appears as printed using the internet browser’s default PDF printing mechanism on October 21, 2025. Petitioners recognized that the article as printed was “incomplete,” *see* Paper 21 at 2, so they reproduced the article in full as EX1026. The article is accessible at <https://artbio.com/artbio-nucleus-radiopharma-collaboration-manufacture-gmp-grade-therapeutic-products-radioisotope-pb-212-support-emerging-clinical-trials>.

12. I submitted Exhibit EX1029 in support of Petitioner’s reply.

13. EX1029 is true and correct copy of a webpage from the National Library of Medicine called, “Study of Alpha Radioligand Therapy AB001 in

Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

(ARTISAN).” It was last updated on April 7, 2026. The article was accessed on April 16, 2026 and is accessible at <https://clinicaltrials.gov/study/NCT07214961>.

14. I submitted Exhibit EX1030 in support of Petitioner’s reply.

15. EX1030 is true and correct copy of a webpage article from Patent Owner ARTBIO’s website called, “ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer” that was published on January 12, 2026. The article was accessed on April 27, 2026 and is accessible at <https://artbio.com/ARTBIO-Announces-dosing-of-Two-Cohorts-with-AB001>.

I declare under penalty of perjury that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

5/14/2026
Date

/s/Jennifer Librach Nall
Jennifer Librach Nall
Reg. No. 57,053
DLA Piper LLP US
303 Colorado Street, Suite 3000
Austin, TX 78701
Phone: + 1 512 457 7249

Fax: + 1 512 721 2249
Jennifer.nall.ptab@us.dlapiper.com
***Attorney for Petitioner, AdvanCell
Isotopes Pty Ltd***

CERTIFICATE OF SERVICE

The undersigned certifies that on May 14, 2026, a true and correct copy of the forgoing document was served by emailing a copy of same (by agreement) to the following attorneys for the Patent Owner:

Michael T. Rosato (mrosato@wsgr.com)

Patrick M. Medley (pmedley@wsgr.com)

Michael J. Hostetler (mhostetler@wsgr.com)

Respectfully submitted,

/s/ Jennifer Librach Nall
Jennifer Librach Nall